Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 39.54B |
| Revenue (ttm) | 2.39B |
| Net Income (ttm) | 32.41M |
| Shares Out | n/a |
| EPS (ttm) | 0.25 |
| PE Ratio | 1,219.88 |
| Forward PE | 37.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 73 |
| Average Volume | 254 |
| Open | 396.05 |
| Previous Close | 396.79 |
| Day's Range | 396.05 - 407.45 |
| 52-Week Range | 209.75 - 500.21 |
| Beta | n/a |
| RSI | 38.96 |
| Earnings Date | Feb 20, 2026 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin... [Read more]
Financial Performance
In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.
Financial numbers in USD Financial StatementsNews
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 5 years by 10.35% on an annualized basis producing an average annual return of 23.17%. Currently, Alnylam Pharmaceutic...
Alnylam To Expand Massachusetts Manufacturing Facility With $250 Million Investment
(RTTNews) - Alnylam Pharmaceuticals (ALNY) on Wednesday said it plans to expand its manufacturing facility in Norton, Massachusetts, with an investment of about $250 million. The expansion is intended...
Alnylam (ALNY) Advances Norton Facility with $250M Investment
Alnylam (ALNY) Advances Norton Facility with $250M Investment
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing faci...
Is Alnylam Entering A Corrective Phase After A Strong Run?
Alnylam (NASDAQ: ALNY) has corrected by roughly 13% over the past couple of weeks. To understand why this pullback is unfolding now, it is important to examine the stock's structure through the lens ...
Is Alnylam Entering A Corrective Phase After A Strong Run?
Alnylam (NASDAQ: ALNY) has corrected by roughly 13% over the past couple of weeks. To understand why this pullback is unfolding now, it is important to examine the stock's structure through the lens o...
Oversold Conditions For Alnylam Pharmaceuticals (ALNY)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Alnylam Pharmaceuticals (ALNY) Rating Maintained, Price Target Lowered by Leerink Partners | ...
Alnylam Pharmaceuticals (ALNY) Rating Maintained, Price Target Lowered by Leerink Partners | ALNY Stock News
Alnylam, Seagate among six stocks added to Nasdaq-100 in annual rebalance
Nasdaq-100 Shake-Up: These 6 Stocks Are In, 6 Are Out — And It Could Trigger Big Moves
The Nasdaq-100 Index has announced its annual reconstitution, adding six new companies and removing six, effective Dec. 22. Six Stocks Added, Six Dropped From Index The six companies being added to th...
Alnylam Pharmaceuticals: Challenges In The TTR Space And Few Late-Stage Catalysts Are A Concern
Explore Alnylam Pharmaceuticals' outlook as TTR franchise growth, competitive pressures, and valuation create a potential 'buy the dip' investment.
Walmart was too late for a Nasdaq-100 spot — but these 6 stocks made the cut
Six companies will join the Nasdaq-100 later this month — but not Walmart, which switched its listing away from the New York Stock Exchange too late to qualify for a spot in the tech-heavy index.
Alnylam (ALNY) and Seagate (STX) Join Nasdaq 100 Index
Alnylam (ALNY) and Seagate (STX) Join Nasdaq 100 Index
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions
Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others considered for additions. Read more here.
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
Eight stock picks to play one of the healthiest corners of the market
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull mar...
Alnylam (ALNY) Announces $34.4M Convertible Notes Repurchase
Alnylam (ALNY) Announces $34.4M Convertible Notes Repurchase
ALNY: Stifel Raises Price Target to $508, Maintains Buy Rating | ALNY Stock News
ALNY: Stifel Raises Price Target to $508, Maintains Buy Rating | ALNY Stock News
Alnylam announces partial repurchase of convertible notes due 2027
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotia...
Is Alnylam Pharmaceuticals a Millionaire Maker?
Alnylam has been a big winner for investors since its IPO in 2004. The drugmaker's future looks promising.
Noteworthy ETF Inflows: CGGR, TDG, ALNY, DHI
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Capital Group Growth ETF (Symbol: CGGR) where we have detected an appr...
Alnylam Pharmaceuticals Announces Changes to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of tw...
Options Movement At Alnylam Pharmaceuticals: Yvonne Greenstreet Exercises Worth $1.72M
Disclosed in a recent SEC filing on December 1, Greenstreet, Chief Executive Officer at Alnylam Pharmaceuticals (NASDAQ: ALNY), made a noteworthy transaction involving the exercise of company stock o...